Neptune Acquires Common Shares of Acasti Pharma
2012年2月13日 - 10:00PM
Neptune Technologies & Bioressources Inc.
("
Neptune") (Nasdaq:NEPT) (TSX-V:NTB) announces
that on February 10, 2012 it acquired 750,000 newly issued Class
"A" common shares (the "
Shares") in the capital of
Acasti Pharma Inc. (TSX-V:APO) ("
Acasti"), a
subsidiary of Neptune. The Shares were acquired at a price of $1.33
CAD per Share for an aggregate consideration of $1,000,000 CAD
pursuant to a subscription agreement (the "
Subscription
Agreement") entered into with Acasti which contained
customary terms and conditions. The Subscription Agreement was
entered into as part of a private placement of Shares pursuant to
which Acasti raised approximately $2,000,000 CAD (the
"
Private Placement").
Before the closing of the Private Placement, Neptune held
40,617,733 Shares, representing 57% of the issued and outstanding
Shares in the capital of Acasti at that time. After completion of
the Private Placement, Neptune now has beneficial ownership and
control over 41,367,733 Shares, representing 57% of the issued and
outstanding Shares in the capital of Acasti. Following Neptune
investment the Corporation will potentially hold more than 50% of
the fully diluted number of Shares of Acasti.
"It has always been Neptune's strategy to restrain and
avoid any dilution of our ownership in Acasti and we demonstrate
that once again by participating in this private placement
financing. We also welcome and value Dr.
Harlan Waksal's collaboration and partnership in our
subsidiary and believe his input will
contribute in reaching Acasti's objectives," stated André
Godin, CFO.
The securities issued to Neptune as part of the Private
Placement were distributed pursuant to an exemption from the
prospectus requirements as set out in National Instrument 45-106 -
Prospectus and Registration Exemptions. The Shares issued to
Neptune as part of the Private Placement are subject to a statutory
four-month hold period.
The Private Placement is a private transaction and therefore was
not realized through the facilities of any stock exchange or other
market.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipids products for the nutraceutical and
pharmaceutical markets. Neptune focuses on growing consumer health
markets, including cardiovascular, inflammatory and neurological
diseases, driven by consumers taking a more proactive approach to
managing health and preventing diseases. Neptune sponsors clinical
trials aimed to demonstrate its product health benefits and to
obtain regulatory approval for label health claims. Neptune is
continuously expanding its intellectual property portfolio as well
as clinical studies and regulatory approvals. Neptune's products
are marketed and distributed in over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti is focusing initially
on treatments for chronic cardiovascular and cardiometabolic
conditions within the over-the-counter, medical food and
prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm Inc. is pursuing pharmaceutical neurological
applications and a clinical study for a medical food product with a
multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational
partners.
"Neither Nasdaq nor the TSX nor its Regulation Services Provider
(as that term is defined in the policies of the TSX ) accepts
responsibility for the adequacy or accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024